A schizophrenia-linked mutation in PIP5K2A fails to activate neuronal M channels

Psychopharmacology

Volumn 199, Issue 1, 2008, Pages 47-54

  Fedorenko, Olga ^a,b   Strutz Seebohm, Nathalie ^a,d   Henrion, Ulrike ^a,d   Ureche, Oana N ^a   Lang, Florian ^a   Seebohm, Guiscard ^a,d   Lang, Undine E ^c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b MENTAL HEALTH RESEARCH INSTITUTE   (Russian Federation)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Addiction; Channel; Dopamine; KCNQ; Kinase; Mutation; PIP2; Potassium; Schizophrenia

Indexed keywords

COCAINE; DOPAMINE; M CHANNEL; METHYLPHENIDATE; MUTANT PROTEIN; PHENCYCLIDINE; PHOSPHATIDYLINOSITOL 4 PHOSPHATE KINASE; PHOSPHATIDYLINOSITOL 4 PHOSPHATE KINASE 2ALPHA; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; POTASSIUM CHANNEL KCNQ; POTASSIUM CHANNEL KCNQ2; POTASSIUM CHANNEL KCNQ3; POTASSIUM CHANNEL KCNQ5;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOPAMINERGIC NERVE CELL; ENZYME ACTIVATION; GENE MUTATION; NERVE CELL EXCITABILITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; SCHIZOPHRENIA; XENOPUS;

ALLELES; ANIMALS; DNA MUTATIONAL ANALYSIS; DOPAMINE; HUMANS; KCNQ POTASSIUM CHANNELS; NEURONS; OOCYTES; PATCH-CLAMP TECHNIQUES; PHENOTYPE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); SCHIZOPHRENIA; SUBSTRATE SPECIFICITY; XENOPUS LAEVIS;

EID: 46149095948     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-008-1095-x     Document Type: Article

References (43)

1. Anderson RA, Boronenkov IV, Doughman SD, Kunz J, Loijens JC (1999) Phosphatidylinositol phosphate kinases, a multifaceted family of signaling enzymes. J Biol Chem 274:9907-9910
2. Bakker SC, Hoogendoorn ML, Hendriks J, Verzijlbergen K, Caron S, Verduijn W, Selten JP, Pearson PL, Kahn RS, Sinke RJ (2007) The PIP5K2A and RGS4 genes are differentially associated with deficit and non-deficit schizophrenia. Genes Brain Behav 6:113-119
3. Bar KJ, Koschke M, Boettger MK, Berger S, Kabisch A, Sauer H, Voss A, Yeragani VK (2007) Acute psychosis leads to increased QT variability in patients suffering from schizophrenia. Schizophr Res 95:115-123
4. Blackburn-Munro G, Dalby-Brown W, Mirza NR, Mikkelsen JD, Blackburn-Munro RE (2005) Retigabine: chemical synthesis to clinical application. CNS Drug Rev 11:1-20
5. Brown DA, Hughes SA, Marsh SJ, Tinker A (2007) Regulation of M(Kv7.2/7.3) channels in neurons by PIP2 and products of PIP2 hydrolysis: significance for receptor-mediated inhibition. J Physiol 582:917-925
6. Bubser M, Deutch AY (2002) Differential effects of typical and atypical antipsychotic drugs on striosome and matrix compartments of the striatum. Eur J Neurosci 15:713-720
7. Dalby-Brown W, Hansen HH, Korsgaard MP, Mirza N, Olesen SP (2006) K(v)7 channels: function, pharmacology and channel modulators. Curr Top Med Chem 6:999-1023
8. Delmas P, Brown DA (2005) Pathways modulating neural KCNQ/M (Kv7) potassium channels. Nat Rev Neurosci 6:850-862
9. Doughman RL, Firestone AJ, Wojtasiak ML, Bunce MW, Anderson RA (2003) Membrane ruffling requires coordination between type I phosphatidylinositol phosphate kinase and Rac signaling. J Biol Chem 278:M211397200
10. Guex N, Peitsch MC (1997) SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18:2714-2723
11. Guillin O, Abi-Dargham A, Laruelle M (2007) Neurobiology of dopamine in schizophrenia. Int Rev Neurobiol 78:1-39
12. Gupta PD, Johar K, Vasavada A (2004) Causative and preventive action of calcium in cataracto-genesis. Acta Pharmacol Sin 25:1250-1256
13. Hansen HH, Ebbesen C, Mathiesen C, Weikop P, Ronn LC, Waroux O, Scuvée-Moreau J, Seutin V, Mikkelsen JD (2006) The KCNQ channel opener retigabine inhibits the activity of mesencephalic dopaminergic systems of the rat. J Pharmacol Exp Ther 318:1006-1019
14. Hansen HH, Andreasen JT, Weikop P, Mirza N, Scheel-Krüger J, Mikkelsen JD (2007) The neuronal KCNQ channel opener retigabine inhibits locomotor activity and reduces forebrain excitatory responses to the psychostimulants cocaine, methylphenidate and phencyclidine. Eur J Pharmacol 570:77-88
15. He Z, Li Z, Shi Y, Tang W, Huang K, Ma G, Zhou J, Meng J, Li H, Feng G, He L (2007) The PIP5K2A gene and schizophrenia in the Chinese population-a case-control study. Schizophr Res 94:359-365
16. Hu H, Vervaeke K, Storm JF (2007) M-channels (Kv7/KCNQ channels) that regulate synaptic integration, excitability, and spike pattern of CA1 pyramidal cells are located in the perisomatic region. J Neurosci 27:1853-1867
17. Jentsch TJ, Schroeder BC, Kubisch C, Friedrich T, Stein V (2000) Pathophysiology of KCNQ channels: neonatal epilepsy and progressive deafness. Epilepsia 41:1068-1069
18. Korsgaard MP, Hartz BP, Brown WD, Ahring PK, Strobaek D, Mirza NR (2005) Anxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels. J Pharmacol Exp Ther 314:282-292
19. Koyama S, Appel SB (2006) Characterization of M-current in ventral tegmental area dopamine neurons. J Neurophysiol 96:535-543
20. Lang F, Klingel K, Wagner CA, Stegen C, Warntges S, Friedrich B, Lanzendorfer M, Melzig J, Moschen I, Steuer S, Waldegger S, Sauter M, Paulmichl M, Gerke V, Risler T, Gamba G, Capasso G, Kandolf R, Hebert SC, Massry SG, Broër S (2000) Deranged transcriptional regulation of cell-volume-sensitive kinase hSGK in diabetic nephropathy. Proc Natl Acad Sci U S A 97:8157-8162
21. Lang UE, Puls I, Muller DJ, Strutz-Seebohm N, Gallinat J (2007) Molecular mechanisms of schizophrenia. Cell Physiol Biochem 20:687-702
22. Lerche H, Weber YG, Jurkat-Rott K, Lehmann-Horn F (2005) Ion channel defects in idiopathic epilepsies. Curr Pharm Des 11:2737-2752
23. + channel open probability by phosphatidylinositol 4,5-bisphosphate. J Neurosci 25:9825-9835
24. Lieberman JA, Kane JM, Sarantakos S, Gadaleta D, Woerner M, Alvir J, Ramos-Lorenzi J (1987) Prediction of relapse in schizophrenia. Arch Gen Psychiatry 44:597-603
25. Lieberman JA, Kane JM, Johns CA (1989) Clozapine: guidelines for clinical management. J Clin Psychiatry 50:329-338
26. Marquez MF, Ramos-Kuri M, Hernandez-Pacheco G, Estrada J, Fabregat JR, Perez-Vielma N, Gómez-Flores J, González-Hermosillo A, Cárdenas M, Vargas-Alarcón G (2006) (KCNQ 1 (KvLQT1) missense mutation causing congenital long QT syndrome (Jervell-Lange-Nielsen) in a Mexican family). Arch Cardiol Mex 76:257-262
27. Martire M, D'Amico M, Panza E, Miceli F, Viggiano D, Lavergata F, Iannotti FA, Barrese V, Preziosi P, Annunziato L, Taglialatela M (2007) Involvement of KCNQ2 subunits in (3H)dopamine release triggered by depolarization and pre-synaptic muscarinic receptor activation from rat striatal synaptosomes. J Neurochem 102:179-193
28. McLaughlin S, Wang J, Gambhir A, Murray D (2002) PI4,5P(2) and proteins: interactions, organization, and information flow. Annu Rev Biophys Biomol Struct 31:151-175
29. Mikkelsen JD (2004) The KCNQ channel activator retigabine blocks haloperidol-induced c-Fos expression in the striatum of the rat. Neurosci Lett 362:240-243
30. Piccinin S, Randall AD, Brown JT (2006) KCNQ/Kv7 channel regulation of hippocampal gamma-frequency firing in the absence of synaptic transmission. J Neurophysiol 95:3105-3112
31. Rameh LE, Tolias KF, Duckworth BC, Cantley LC (1997) A new pathway for synthesis of phosphatidylinositol-4,5 bisphosphate. Nature 390:192-196
32. Rohacs T, Chen J, Prestwich GD, Logothetis DE (1999) Distinct specificities of inwardly rectifying K(+) channels for phosphoinositides. J Biol Chem 274:36065-36072
33. Schmidt WJ, Schuster G, Wacker E, Pergande G (1997) Antiparkinsonian and other motor effects of flupirtine alone and in combination with dopaminergic drugs. Eur J Pharmacol 327:1-9
34. Schwab SG, Knapp M, Sklar P, Eckstein GN, Sewekow C, Borrmann-Hassenbach M, Albus M, Becker T, Hallmayer JF, Lerer B, Maier W, Wildenauer DB (2006) Evidence for association of DNA sequence variants in the phosphatidylinositol-4- phosphate 5-kinase IIalpha gene (PIP5K2A) with schizophrenia. Mol Psychiatry 11:837-846
35. Shyng SL, Barbieri A, Gumusboga A, Cukras C, Pike L, Stahl PD, Nichols CG (2000) Modulation of nucleotide sensitivity of ATP-sensitive potassium channels by phosphatidylinositol-4-phosphate 5-kinase. Proc Natl Acad Sci U S A 97:937-941
36. Stone JM, Pilowsky LS (2007) Novel targets for drugs in schizophrenia. CNS Neurol Disord Drug Targets 6:265-272
37. Stopkova P, Saito T, Fann CS, Papolos DF, Vevera J, Zukov I, Stryjer R, Strous RD, Lachman HM (2003) Polymorphism screening of PIP5K2A: a candidate gene for chromosome 10p-linked psychiatric disorders. Am J Med Genet B Neuropsychiatr Genet 123:50-58
38. Stopkova P, Vevera J, Paclt I, Zukov I, Papolos DF, Saito T, Lachman HM (2005) Screening of PIP5K2A promoter region for mutations in bipolar disorder and schizophrenia. Psychiatr Genet 15:223-227
39. Suh BC, Inoue T, Meyer T, Hille B (2006) Rapid chemically induced changes of PtdIns(4,5)P2 gate KCNQ ion channels. Science 314:1454-1457
40. Thirthalli J, Benegal V (2006) Psychosis among substance users. Curr Opin Psychiatry 19:239-245
41. Vervaeke K, Gu N, Agdestein C, Hu H, Storm JF (2006) Kv7/KCNQ/M-channels in rat glutamatergic hippocampal axons and their role in regulation of excitability and transmitter release. J Physiol 576:235-256
42. Wagner CA, Friedrich B, Setiawan I, Lang F, Broer S (2000) The use of Xenopus laevis oocytes for the functional characterization of heterologously expressed membrane proteins. Cell Physiol Biochem 10:1-12
43. Zhang H, Craciun LC, Mirshahi T, Rohacs T, Lopes CM, Jin T, Logothetis DE (2003) PIP(2) activates KCNQ channels, and its hydrolysis underlies receptor-mediated inhibition of M currents. Neuron 37:963-975